Rossing, Peter

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial

Filippatos, G., Anker, S. D., Agarwal, R., Ruilope, L. M., Rossing, P., Bakris, G. L., Tasto, C., Joseph, A., Kolkhof, P., Lage, A., et al. (2022) · Circulation

Chronic Kidney Disease and DiabetesHeart Failure Treatment and Management

Cited by 299

Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes

Filippatos, G., Anker, S. D., Agarwal, R., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Schloemer, P., Tornus, I., Joseph, A., et al. (2021) · Circulation

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 294

Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment

de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 278

Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence

Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 274

Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER

Shaman, A. M., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Mann, J. F. E., Nauck, M. A., Rasmussen, S., Rossing, P., et al. (2022) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 255

Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update

Navaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Liew, A., Michos, E. D., Olowu, W. A., Sadusky, T., et al. (2023) · Annals of Internal Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 248

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

Rossing, P., Baeres, F. M. M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S. C. L., Idorn, T., Lawson, J., Mahaffey, K. W., Mann, J. F. E., et al. (2023) · Nephrology Dialysis Transplantation

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 242

Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial

Davies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A., & Umpierrez, G. E. (2016) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 235

Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

Currie, G., Taylor, A. H. M., Fujita, T., Ohtsu, H., Lindhardt, M., Rossing, P., Boesby, L., Edwards, N. C., Ferro, C. J., Townend, J. N., et al. (2016) · BMC Nephrology

Hormonal Regulation and HypertensionChronic Kidney Disease and Diabetes

Cited by 214

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial

Pollock, C., Stefánsson, B., Reyner, D., Rossing, P., Sjöström, C. D., Wheeler, D. C., Langkilde, A. M., & Heerspink, H. J. L. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 205

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

Mann, J. F. E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D. M., Hadjadj, S., Gillard, P., Górriz, J. L., et al. (2024) · Nature Medicine

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 200

Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy

Nielsen, F. S., Rossing, P., Gall, M. A., Skott, P., Smidt, U. M., & Parving, H. H. (1997) · Diabetes

Chronic Kidney Disease and DiabetesBlood Pressure and Hypertension Studies

Cited by 182

Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function-even without albuminuria

Vistisen, D., Andersen, G. S., Hulman, A., Persson, F., Rossing, P., & Jørgensen, M. E. (2019) · Diabetes Care

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 167

Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials

Mann, J. F. E., Hansen, T., Idorn, T., Leiter, L. A., Marso, S. P., Rossing, P., Seufert, J., Tadayon, S., & Vilsbøll, T. (2020) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 157

Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes

Filippatos, G., Bakris, G. L., Pitt, B., Agarwal, R., Rossing, P., Ruilope, L. M., Butler, J., Lam, C. S. P., Kolkhof, P., Roberts, L., et al. (2021) · Journal of the American College of Cardiology

Atrial Fibrillation Management and OutcomesChronic Kidney Disease and Diabetes

Cited by 153

LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial.

Game, F., Jeffcoate, W., Tarnow, L., Jacobsen, J. L., Whitham, D. J., Harrison, E. F., Ellender, S. J., Fitzsimmons, D., Löndahl, M., Dhatariya, K., et al. (2018) · The Lancet Diabetes & Endocrinology

Diabetic Foot Ulcer Assessment and ManagementWound Healing and Treatments

Cited by 147

Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial

Pratley, R. E., Tuttle, K. R., Rossing, P., Rasmussen, S., Perkovic, V., Nielsen, O. W., Mann, J. F. E., MacIsaac, R. J., Kosiborod, M. N., Kamenov, Z., et al. (2024) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 132

Combination therapy for kidney disease in people with diabetes mellitus

van Raalte, D. H., Bjornstad, P., Cherney, D. Z. I., de Boer, I. H., Fioretto, P., Gordin, D., Persson, F., Rosas, S. E., Rossing, P., Schaub, J. A., et al. (2024) · Nature Reviews Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 127

SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation

Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2021) · Diabetes

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 123

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis

Agarwal, R., Tu, W., Farjat, A. E., Farag, Y. M. K., Toto, R., Kaul, S., Lawatscheck, R., Rohwedder, K., Ruilope, L. M., Rossing, P., et al. (2023) · Annals of Internal Medicine

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 109

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone

Agarwal, R., Anker, S. D., Bakris, G., Filippatos, G., Pitt, B., Rossing, P., Ruilope, L., Gebel, M., Kolkhof, P., Nowack, C., et al. (2022) · Nephrology Dialysis Transplantation

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 103

Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study

Oellgaard, J., Gæde, P., Rossing, P., Rørth, R., Køber, L., Parving, H.-H., & Pedersen, O. (2018) · Diabetologia

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 86

Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)

Boer, I. H. D., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022)

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 79

Efficacy and safety of dapagliflozin by baseline glycemic status: a prespecified analysis from the DAPA-CKD trial

Persson, F., Rossing, P., Vart, P., Chertow, G. M., Hou, F. F., Jongs, N., McMurray, J. J. V., Correa-Rotter, R., Bajaj, H. S., Stefansson, B. V., et al. (2021) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 78